


**CLAIM LISTING**

Claim 1 (Previously Presented): A method for promoting colon adenocarcinoma cell differentiation, comprising treating a colon adenocarcinoma cell with a bilin.

Claims 2-9 (Cancelled)

Claim 10 (Previously Presented): A method for promoting differentiation of a colon adenocarcinoma cell, comprising treating a colon adenocarcinoma cell with a bilin represented by the general formula (I):



wherein W represents -CL<sub>2</sub>-, -C(=O)-, -C(=S)-, -C(=NH)-, or =CL-;

X represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

Y represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

Z represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

A represents -NH- or -N=;

B represents a trisubstituted, sp<sup>2</sup>-hybridized carbon atom;

K represents =CL- or -CL<sub>2</sub>-; and

L represents H or lower alkyl.

Claims 11-13 (Cancelled)

USSN 09/977,866

3

Facsimile Filing may 20, 2004

Claim 14 (Original): The method of claim 10, wherein the cell is contacted with the bilin *in vitro*.

Claim 15 (Original): The method of claim 10, wherein the cell is contacted with the bilin *in vivo*.

Claim 16 (Previously Presented): The method of claim 15, wherein the bilin is administered as part of a therapeutic application.

Claim 17 (Cancelled)

Claim 18 (Cancelled)

Claim 19 (Cancelled)

Claim 20 (Currently Amended): A method for promoting colon adenocarcinoma cell differentiation ~~A method for treating unwanted cell proliferation~~, comprising administering to a patient ~~a~~ [[the]] pharmaceutical preparation of ~~claim 18 or 19~~ comprising a sterile pharmaceutical excipient and a bilin.


Claim 21 (Original): The method of claim 1, wherein the bilin is bilirubin or biliverdine.

Claim 22 (Cancelled)

Claim 23 (Original): The method of claim 10, wherein the bilin is bilirubin or biliverdine.

Claim 24 (Cancelled)

Claim 25 (New): A method for promoting colon adenocarcinoma cell differentiation, comprising administering to a patient a pharmaceutical preparation comprising a sterile pharmaceutical excipient and a bilin represented by the general formula (I):



wherein W represents  $-\text{CL}_2-$ ,  $-\text{C}(=\text{O})-$ ,  $-\text{C}(=\text{S})-$ ,  $-\text{C}(=\text{NH})-$ , or  $=\text{CL}-$ ;

X represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

Y represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

Z represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

A represents  $-\text{NH}-$  or  $-\text{N}=-$ ;

B represents a trisubstituted,  $\text{sp}^2$ -hybridized carbon atom;

K represents  $=\text{CL}-$  or  $-\text{CL}_2-$ ; and

L represents H or lower alkyl.